Nguyen Dang, MD
Hospitalist · Anaheim, CANPI 1679671622
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,805 of the $6,130 with a category attached, or 62.1%. 34 manufacturers reported payments, led by Gilead at 39.4% of the total. Reporting peaked in 2021 at $2,301 and has fallen 69.0% since, to $714 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $34.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Johnson & Johnson$611
- AbbVie$576
- GSK$295
- Bayer$281
- Pfizer$264
- plus $2K from 28 others
Across 3 payments — averaging $4.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$15
What the payments were for
- Consulting fees$2,32538%
- Food & beverage$3,80562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 9 | $2,417 |
| Johnson & Johnson | 36 | $611 |
| AbbVie(2 entities) | 26 | $576 |
| GSK | 14 | $295 |
| Bayer | 13 | $281 |
| Pfizer | 14 | $264 |
| AstraZeneca(2 entities) | 4 | $182 |
| E.r. Squibb & Sons, L.L.C. | 3 | $155 |
| Alkermes, Inc. | 6 | $130 |
| Novartis | 7 | $128 |
| Boston Scientific | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Amgen | 4 | $84 |
| Lilly USA, LLC | 4 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Stryker | 2 | $56 |
| Novo Nordisk | 3 | $56 |
| Dexcom, Inc. | 2 | $53 |
| Merck | 3 | $49 |
| Lundbeck LLC | 2 | $48 |
| Boehringer Ingelheim | 2 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Grifols USA, LLC | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| Electromed, Inc. | 1 | $19 |
| Inari Medical, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,130 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $57,597 |
| MounjaroTirzepatide | 20 | $27,745 |
| XareltoRivaroxaban | 41 | $26,304 |
| JardianceEmpagliflozin | 25 | $25,773 |
| SantylCollagenase Clostridium Hist. | 11 | $24,216 |
| JanuviaSitagliptin Phosphate | 20 | $20,520 |
| LinzessLinaclotide | 11 | $16,322 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $16,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,184 |
| FarxigaDapagliflozin Propanediol | 11 | $9,434 |
| MyrbetriqMirabegron | 21 | $8,009 |
| Sucralfate | 16 | $5,342 |
| AlogliptinAlogliptin Benzoate | 14 | $3,391 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $3,119 |
| Atorvastatin Calcium | 310 | $3,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $264 | $57,597119 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $46 | $41,81257 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $80 | $30,10032 claims |
| Johnson & JohnsonXarelto | $611 | $26,30441 claims |
| MerckJanuvia | $49 | $20,52020 claims |
| AbbVieLinzess | $576 | $16,32211 claims |
| GSKTrelegy Ellipta | $295 | $11,18419 claims |
| AstraZenecaFarxiga | $182 | $9,43411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Anaheim
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
- Summaiya MuhammadCastro Valley$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.